GRI Bio (GRI) Expected to Announce Quarterly Earnings on Thursday

GRI Bio (NASDAQ:GRI) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($1.20) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:00 PM ET.

GRI Bio (NASDAQ:GRI) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.01). On average, analysts expect GRI Bio to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

GRI Bio Trading Up 15.6%

Shares of NASDAQ:GRI opened at $1.70 on Tuesday. The stock has a fifty day simple moving average of $1.78 and a two-hundred day simple moving average of $2.31. The stock has a market capitalization of $3.01 million, a price-to-earnings ratio of -0.02 and a beta of -1.20. GRI Bio has a 12-month low of $1.36 and a 12-month high of $80.36.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GRI. Weiss Ratings restated a “sell (e+)” rating on shares of GRI Bio in a report on Friday, July 17th. Ascendiant Capital Markets dropped their price target on shares of GRI Bio from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $32.00.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.